Health Canada acknowledges public demand for cheaper generic options for the popular drug Ozempic. Several companies have filed for authorization, though timelines are unclear. Patients may face delays in accessing these alternatives.
In an email to The Canadian Press, Health Canada spokesperson Mark Johnson expressed recognition of substantial enthusiasm for decreasing expenses tied to this frequently prescribed medication via the launch of generic variants.
Based on the agency's roster of generic applications, companies such as Sandoz Canada, Apotex, Teva Canada, Taro Pharmaceuticals, and Aspen Pharmacare Canada have submitted their requests for authorization.
Track your medication journey
Join thousands using Shotlee to track GLP-1 medications.
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
While Sandoz Canada and Teva Canada declined to share details on anticipated rollout schedules for their offerings, the remaining entities either remained unreachable or opted not to reply to inquiries.
Johnson explained that the unnamed firms submitted their proposals before April 1, 2024, when the rule mandating sponsor disclosure was updated, hence their exclusion from the list. Individuals aiming to track their health metrics effectively could explore tools like health tracking apps such as Shotlee to oversee their wellness journey.
Original source: Toronto Sun
View original article →Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.
Demi Moore turned heads at Milan Fashion Week with a short wet-look bob and all-black leather outfit, but fans are worried she's an 'Ozempic victim' due to her slim appearance. While Ozempic (semaglutide) is linked to rapid weight loss in Hollywood, there's no evidence the actress uses it. Discover the truth and what this means for GLP-1 medications.
Novo Nordisk's Ozempic pioneered the GLP-1 revolution, tripling sales to 309 billion DKK in eight years. Yet shares have cratered 60% due to Eli Lilly's Mounjaro gains, trial disappointments, and looming generics. Discover the booming market's challenges and opportunities.
